Thursday, June 4, 2020, 5:00 PM – 6:30 PM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from PracticeA Complimentary CNE (NCPD) Live Webinar Series

Chronic Lymphocytic Leukemia

Register Today for This CNE (NCPD) Virtual Event — 1.5 Credit Hours Available

Live Webinar

Join Us on Thursday, June 4
5:00 PM – 6:30 PM ET

Complimentary Registration
A link to the event will be provided after registration.


Amy Goodrich, CRNP
Nurse Practitioner
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins Medicine
Baltimore, Maryland

Brad S Kahl, MD
Professor of Medicine
Washington University School of Medicine
Director, Lymphoma Program
Siteman Cancer Center
St Louis, Missouri

Robin Klebig, APRN, CNP, AOCNP
Nurse Practitioner
Division of Hematology
Mayo Clinic
Rochester, Minnesota

Jeff Sharman, MD
Willamette Valley Cancer Institute
and Research Center
Medical Director of Hematology Research
US Oncology
Eugene, Oregon


Neil Love, MD
Research To Practice
Miami, Florida

Topics for Discussion

  • Module 1: Front-Line Management of Chronic Lymphocytic Leukemia (CLL) in Older Patients
  • Module 2: Front-Line Management of CLL in Younger, Fit Patients
  • Module 3: Emerging Evidence with Second-Generation Bruton Tyrosine Kinase Inhibitors for CLL
  • Module 4: Treatment Options and Emerging Regimens for Relapsed/Recurrent CLL
A detailed agenda will be made available in the coming weeks.

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of chronic lymphocytic leukemia (CLL).

Learning Objectives and Goals
Upon completion of this activity, participants should be able to:

  • Appreciate the importance of clinical presentation, biomarker profile, coexisting medical conditions and psychosocial status in the selection of systemic therapy for newly diagnosed CLL.
  • Evaluate available and emerging Phase III data demonstrating the superior efficacy and safety of Bruton tyrosine kinase and Bcl-2 inhibition compared to standard chemoimmunotherapy as first-line therapy for patients with treatment-naïve CLL, and use this information to discern how, if at all, these strategies can be optimally integrated into nonresearch care algorithms.
  • Recognize how published research data, prior therapeutic exposure and the results of biomarker analyses may influence the selection and sequencing of therapy in order to counsel patients with relapsed/refractory CLL about the rationale for individualized treatment recommendations.
  • Design and implement a plan of care to recognize and manage side effects and toxicities associated with existing and recently approved systemic therapies for patients with CLL to support quality of life and continuation of therapy.
  • Recall available and emerging data with investigational agents and strategies currently in Phase III testing for CLL, and, as applicable, educate eligible patients about clinical trial participation.
  • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with CLL to optimize clinical and quality-of-life outcomes.
Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form, which will be emailed to attendees after the event.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for CNE (NCPD) credit to utilize this program for ONCC certification or renewal.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE (NCPD) activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

RTP CNE (NCPD) planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, and Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.